(Total Views: 664)
Posted On: 10/27/2020 11:16:24 AM
Post# of 154286
After seeing a couple of other posts, I should add that even a lower market share, and a lower price point will go a long way to solving our money challenges.
Forgive my rough numbers.
If our burn rate is, say $10mm per month, and the UK HIV approval only nets $30mm per year in revenue. This would still leave us $90mm short per year.
However, the increase in the share price that comes with an approval and some revenue will make dilution much more palatable, and quite likely ensure we uplist to Nasdaq.
If, say the resulting share price is $8/share, we would need to dilute less than 12mm shares per year.
Forgive my rough numbers.
If our burn rate is, say $10mm per month, and the UK HIV approval only nets $30mm per year in revenue. This would still leave us $90mm short per year.
However, the increase in the share price that comes with an approval and some revenue will make dilution much more palatable, and quite likely ensure we uplist to Nasdaq.
If, say the resulting share price is $8/share, we would need to dilute less than 12mm shares per year.
(0)
(0)
